Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. - Wikidata - wikimedia - TriplyDB

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q35178966

about

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning How I treat acute lymphoblastic leukemia in older adolescents and young adults New Therapeutic Strategies in Acute Lymphocytic Leukemia.Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.Treatment of Young Adults with Acute Lymphoblastic Leukemia.Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults.Continuing challenges and current issues in acute lymphoblastic leukemia.The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Advances in adult acute lymphoblastic leukemia therapy.A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.Adolescents with Cancer in Italy: Improving Access to National Cooperative Pediatric Oncology Group (AIEOP) Centers.Comparison of survival of adolescents and young adults with hematologic malignancies in Osaka, Japan.Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance?BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers.Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.Role of clinical trials in survival progress of American adolescents and young adults with cancer-and lack thereof.Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.

P2860

Q26738640-85C899AF-F638-4207-8BBA-F64936339FB5 Q26795740-ADE9418A-4B8B-41CB-9F0A-B000CC3BF7FD Q28087589-E687AE27-F76C-44D4-B57D-FA04006DDDFD Q30252776-0412254B-93A9-4611-808E-AD4F3D451016 Q31118945-521A18A7-22A3-4323-9888-EA28D5DFAEF5 Q33865329-D45B816E-7D2F-429B-B48C-5DBC2122536F Q36609579-97E54B11-CF5D-4469-B9F0-F622D4C9AB63 Q36965071-A2FED173-4332-4997-BC41-D8B3792DB559 Q37152911-03D77B8D-FC30-4657-953A-8C819CC90B3F Q38392656-979A155B-99D1-4111-B89E-D6B5BF3442BB Q38409519-5E425AD9-F776-4206-B383-930347057D6D Q38602949-2507972E-45B4-4388-ACDD-3825B251CCCB Q38610250-AB47D08C-7335-48EB-AC74-3033471AEE1A Q38777538-C99FF88C-8428-489E-A926-9C75EADA8379 Q38922016-5C36DA59-CB51-4493-890E-B6A3495B2921 Q39194553-DF5D25FD-BB93-4DC0-82B3-BA4AEC3924DF Q39206217-80376FFA-4278-4ABB-BC12-CC5532DF158C Q39296772-935E4C28-7249-4E8F-AD48-3D0B74D55842 Q39366299-790BA174-E988-4037-9AA2-37F1904B7555 Q39387524-4DD9131C-CDF8-40EC-9BBF-1DD98FDCAAF1 Q39396416-2CCC08FC-97A7-43BC-81A7-20FEB23011F1 Q39401736-9519410D-6ABC-4CBB-B01E-24430AF64408 Q39459190-64086B34-2597-4433-BA01-E34B4C7271A4 Q39684863-41404BEC-4BA7-4EEA-A86F-CE71E823BA26 Q39969220-675B2D70-03FE-446D-B565-D34BB2661330 Q40179856-36FC3416-0C61-49A7-A58E-2F81A4F837CB Q40765997-581F7A0C-71DD-43BE-BEFB-DB70C43F2E6C Q40971388-71CC52C4-464B-44B8-8394-FA955C179306 Q41476785-738B7CC7-FBD2-4BDD-BED5-CE56EB1EC7B2 Q42336338-68076B3A-0660-46CD-83F8-B1BBA3F4FE8A Q46427627-6217654C-49F3-41DF-AB30-AEAAC42FCBBF Q47706549-121CFF81-EFC7-4540-9817-A74DA9E7EF7D Q48311791-FD85BE9D-0BD7-4779-823C-4CBD6412E0CA Q48515641-E1FB4B02-4839-4B35-A88C-3134FF0B8181 Q48882156-1B49EAA7-4F28-4EED-BA73-2AE17AF22DF9 Q49818206-F84FEEC4-83D5-448C-9C4C-D70A8B4DF131 Q50501063-4F6F9CA3-9062-417B-A2CC-361EC3E4D2A3 Q52581050-5C575336-583E-47A8-81A1-032D37924757 Q52852382-13FAB57E-5103-4FDD-9CDF-5BC9A094351C Q53713010-8819D5EE-D938-43B7-B32C-872777C396AE

P2860

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q35178966

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@ast

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@en

type

label

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@ast

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@en

prefLabel

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@ast

Long-term outcome of a pediatr ...... acute lymphoblastic leukemia.

@en

P1433

Q35178966-EB1F783F-B6B4-4D32-A2D2-898F025B4A5B

P1476

Q35178966-4D687EC5-818E-4944-B1A1-F5FF1AE97060

P2093

Q35178966-03BEC032-01BC-4CAA-AE9E-6CF8B08EBD45

Q35178966-103CB936-311A-45BD-A5B7-3DB617A9BF38

Q35178966-104C8CA7-5BFD-4BC2-BE7D-88F6ADFC3BC5

Q35178966-27F33AEB-50C4-41A1-89C1-112EC0526EB2

Q35178966-3507B77C-C028-4D25-A80F-FC993F58A06F

Q35178966-367D1983-6213-4701-B9F1-6A727D788BFB

Q35178966-3C4BA1C8-9068-4A30-A3E9-CC1E5E7DC5C2

Q35178966-3FFD7751-8111-4324-97C8-F4E55F6B22D8

Q35178966-42A7BB7A-A36D-46C8-BAB3-EF52E8B9ACF8

Q35178966-5EA44B42-5607-4B6A-91CB-F98BBDEE4B4C

P2860

Q35178966-0E38D9A1-798F-43C5-92FB-C7AD9D9DAFFC

Q35178966-11F32A4A-8CE1-4379-BC25-7B77D1E0A74F

Q35178966-1B3FE54A-5836-4181-8F65-F3AC578EE23B

Q35178966-2C6CCFBC-6417-4B81-9866-A0A109B9CCCC

Q35178966-336DA318-D3FB-4BA8-A899-183E3ECDA40C

Q35178966-33F3571C-D869-4103-8165-BB0683849C27

Q35178966-34325EC5-CFE0-41B7-9C21-CF806AE31F03

Q35178966-3578431D-43BA-4A50-81A6-AA744C9B0C66

Q35178966-4AC5CD06-7EB5-44DB-BAB0-4BC603FB7E2E

Q35178966-5D600860-EE94-488D-A9DE-29F469BE91CA

P2888

Q35178966-EAE0A772-144C-4270-B35B-6C4E486082D4

P304

Q35178966-DF7FFE0A-4668-4D67-927F-D1C888798745

P31

Q35178966-40EDD113-4F0B-4EBB-8744-5D21637FAF54

P356

Q35178966-E420EF01-B1FB-467E-86C1-A54B9EC10D81

P433

Q35178966-2CC6E845-02D2-45FE-AA8C-712B92A7E2B9

P478

Q35178966-380ED9A7-868B-4E79-A0DC-8042D1ED7749

P50

Q35178966-2E163CD7-E06D-43BE-AF62-5B8718514537

Q35178966-6FDF5018-C1A9-4C1D-8A72-512AFB213AE6

P577

Q35178966-ABDE1428-2D78-4DB1-99A6-5088D8E72C7B

P5875

Q35178966-7848F7B5-7E83-46AA-AC9C-9DD62F19FEFC

P698

Q35178966-38C05F2B-C7FE-405D-B7AD-2AF0AAE27673

P921

Q35178966-A4DAC766-9C26-4FE9-9ED1-A47B86D8E772

P932

Q35178966-75237773-C9E5-4380-BBEC-B3E532D8ABC7

P356

P1433

P1476

Long-term outcome of a pediatr ...... d acute lymphoblastic leukemia

@en

P2093

A R Turner

http://www.w3.org/2001/XMLSchema#string

D J DeAngelo

http://www.w3.org/2001/XMLSchema#string

D S Neuberg

http://www.w3.org/2001/XMLSchema#string

I Galinsky

http://www.w3.org/2001/XMLSchema#string

J G Supko

http://www.w3.org/2001/XMLSchema#string

J H Matthews

http://www.w3.org/2001/XMLSchema#string

K E Stevenson

http://www.w3.org/2001/XMLSchema#string

K Howson-Jan

http://www.w3.org/2001/XMLSchema#string

K K Ballen

http://www.w3.org/2001/XMLSchema#string

K Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.

Outcomes after induction failure in childhood acute lymphoblastic leukemia.

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.

P2888

P304

526-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2014.229

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Suzanne E Dahlberg

P577

2014-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264391370

http://www.w3.org/2001/XMLSchema#string

P698

25079173

http://www.w3.org/2001/XMLSchema#string

P921

P932

4360211

http://www.w3.org/2001/XMLSchema#string